Takeda Pharmaceutical (NYSE:TAK) Releases FY 2026 Earnings Guidance

Posted by Geri Gentry on May 13th, 2026

Takeda Pharmaceutical (NYSE:TAK – Get Free Report) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 3.009-3.009 for the period, compared to the consensus estimate of 1.570. The company issued revenue guidance of $29.6 billion-$29.6 billion, compared to the consensus revenue estimate of $29.0 billion.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. Sanford C. Bernstein upgraded Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a report on Wednesday, April 8th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Takeda Pharmaceutical in a research report on Wednesday, April 29th. Morgan Stanley started coverage on Takeda Pharmaceutical in a research note on Tuesday, January 13th. They set an “overweight” rating for the company. Zacks Research upgraded Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 3rd. Finally, Wall Street Zen upgraded Takeda Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, April 11th. Two investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy”.

Check Out Our Latest Analysis on Takeda Pharmaceutical

Takeda Pharmaceutical Stock Performance

Shares of NYSE TAK opened at $16.43 on Wednesday. The company has a quick ratio of 0.65, a current ratio of 1.19 and a debt-to-equity ratio of 0.56. The firm’s 50-day moving average price is $17.68 and its two-hundred day moving average price is $16.38. Takeda Pharmaceutical has a 52-week low of $12.99 and a 52-week high of $18.90. The stock has a market capitalization of $52.28 billion, a P/E ratio of 68.44 and a beta of -0.06.

Institutional Investors Weigh In On Takeda Pharmaceutical

Hedge funds have recently made changes to their positions in the business. Parkside Financial Bank & Trust raised its holdings in shares of Takeda Pharmaceutical by 192.2% during the fourth quarter. Parkside Financial Bank & Trust now owns 2,560 shares of the company’s stock valued at $40,000 after buying an additional 1,684 shares during the last quarter. Caitong International Asset Management Co. Ltd raised its holdings in shares of Takeda Pharmaceutical by 313.7% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,070 shares of the company’s stock valued at $48,000 after buying an additional 2,328 shares during the last quarter. Northwestern Mutual Wealth Management Co. increased its stake in shares of Takeda Pharmaceutical by 56.3% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company’s stock valued at $55,000 after acquiring an additional 1,292 shares during the period. Advisory Services Network LLC bought a new stake in Takeda Pharmaceutical during the third quarter worth approximately $74,000. Finally, Kestra Advisory Services LLC bought a new stake in Takeda Pharmaceutical during the fourth quarter worth approximately $101,000. Institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Company Profile

(Get Free Report)

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.